Abstract

PAM50 intrinsic subtyping and risk of recurrence (ROR) score are approved for risk profiling in postmenopausal women. We aimed to examine their long-term prognostic value in terms of breast cancer-free interval (BCFi) and overall survival (OS) (n = 437) in premenopausal women randomised to 2 years of tamoxifen versus no systemic treatment irrespective of hormone-receptor status. Intrinsic subtyping added independent prognostic information in patients with oestrogen receptor-positive/human epidermal growth factor 2-negative tumours for BCFi and OS after maximum follow-up (overall P-value 0.02 and 0.006, respectively) and those with high versus low ROR had worse prognosis (maximum follow-up: hazard ratio (HR)BCFi: 1.70, P = 0.04). The prognostic information by ROR was similar regarding OS and in multivariable analysis. These results support that PAM50 subtyping and ROR score provide long-term prognostic information in premenopausal women. Moreover, tamoxifen reduced the incidence of breast cancer events only in patients with Luminal APAM50 tumours (0–10 years: HRBCFi(Luminal A): 0.41, HRBCFi(Luminal B): 1.19, Pinteraction = 0.02).

Trial registration: This trial is registered in the ISRCTN database, trial ID: ISRCTN12474687.

Details

Title
PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients
Author
Lundgren, Christine 1   VIAFID ORCID Logo  ; Pär-Ola, Bendahl 2 ; Church, Sarah E 3 ; Ekholm, Maria 4 ; Fernö Mårten 2   VIAFID ORCID Logo  ; Forsare Carina 2 ; Krüger Ute 2 ; Nordenskjöld Bo 5 ; Stål Olle 5 ; Rydén, Lisa 6   VIAFID ORCID Logo 

1  Department of Oncology, Jönköping, Sweden; Lund University, Department of Clinical Sciences Lund, Division of Oncology, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361) 
2  Lund University, Department of Clinical Sciences Lund, Division of Oncology, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361) 
3  NanoString Technologies, Inc., Seattle, United States (GRID:grid.510973.9) (ISNI:0000 0004 5375 2863) 
4  Department of Oncology, Jönköping, Sweden (GRID:grid.510973.9); Institute of Biomedicine, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska Center for Cancer Research, Department of Laboratory Medicine, Gothenburg, Sweden (GRID:grid.8761.8) (ISNI:0000 0000 9919 9582) 
5  Linköping University, Department of Biomedical and Clinical Sciences, Linköping, Sweden (GRID:grid.5640.7) (ISNI:0000 0001 2162 9922) 
6  Lund University, Department of Clinical Sciences Lund, Division of Surgery, Lund, Sweden (GRID:grid.4514.4) (ISNI:0000 0001 0930 2361); Skåne University Hospital, Department of Surgery, Malmö, Sweden (GRID:grid.411843.b) (ISNI:0000 0004 0623 9987) 
Publication year
2022
Publication date
2022
Publisher
Nature Publishing Group
e-ISSN
23744677
Source type
Scholarly Journal
Language of publication
English
DOI
https://doi.org/10.1038/s41523-022-00423-z
ProQuest document ID
2661273973
Copyright
© The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.